Literature DB >> 24183886

Should full adherence be a necessary goal in schizophrenia? Full versus non-full adherence to antipsychotic treatment.

Francisco J Acosta1, Yolanda Ramallo-Fariña, Samuel G Siris.   

Abstract

There is solid evidence of negative consequences of non-adherence in schizophrenia, and recently adherence has been defined as taking more than 80% of prescribed medication. However, the clinical relevance of different degrees of adherence in adherent patients has not been studied. We evaluated sociodemographic, clinical, treatment-related and psychopathological variables in 78 adherent outpatients with schizophrenia, who were classified into two groups: full-adherence (100% adherence) and non-full adherence (80-99.9%). Adherence was evaluated using electronic monitoring (MEMS®), and the injection record in case of injectable antipsychotics. Non-full adherence patients showed more extensive delusions and guilt feelings, as well as trends toward greater somatic concern, disorientation, general psychopathology, and lower number of prior psychiatric hospitalizations. These finding suggest that the 'fullness' of adherence to antipsychotic treatment is a relevant issue, impacting the psychopathological state of adherent patients with schizophrenia. We found that a large proportion of patients can achieve full adherence, and while 'adherence' is an appropriate objective to be pursued with non-adherent patients, 'full adherence' should be the goal among adherent patients.
© 2014.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24183886     DOI: 10.1016/j.comppsych.2013.09.005

Source DB:  PubMed          Journal:  Compr Psychiatry        ISSN: 0010-440X            Impact factor:   3.735


  4 in total

1.  Getting less of what you want: reductions in statistical power and increased bias when categorizing medication adherence data.

Authors:  Stephen J Tueller; Pascal R Deboeck; Richard A Van Dorn
Journal:  J Behav Med       Date:  2016-02-27

2.  Adherence to Antipsychotic Medication and Quality of Life in Latin-American Patients Diagnosed with Schizophrenia.

Authors:  Alejandra Caqueo-Urízar; Alfonso Urzúa; Patricio Mena-Chamorro; Guillaume Fond; Laurent Boyer
Journal:  Patient Prefer Adherence       Date:  2020-09-03       Impact factor: 2.711

3.  Long-Acting Injectable Antipsychotics in a Prescription Claims Data Source: A Validation Study.

Authors:  Donica Janzen; Reece Ramkissoon; James M Bolton; Christine Leong; I Fan Kuo; Silvia Alessi-Severini
Journal:  Drugs Real World Outcomes       Date:  2022-05-16

4.  Adherence to Antipsychotic Medication and Criminal Recidivism in a Canadian Provincial Offender Population.

Authors:  Stefanie N Rezansoff; Akm Moniruzzaman; Seena Fazel; Lawrence McCandless; Julian M Somers
Journal:  Schizophr Bull       Date:  2017-09-01       Impact factor: 9.306

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.